跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

B109

Sigma-Aldrich

去甲-Binaltorphimine 二盐酸盐

solid

别名:

去甲-BNI 二盐酸盐

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C40H43N3O6 · 2HCl
CAS号:
113158-34-2
分子量:
734.71
MDL號碼:
MFCD00069374
分類程式碼代碼:
12352103
PubChem物質ID:
329773161

形狀

solid

顏色

tan

溶解度

artificial CSF: 2 mg/mL (prepare with sonication for 4 minutes)
H2O: 6.0 mg/mL (aqueous solutions are highly unstable and should be freshly prepared.)
ethanol: soluble

SMILES 字串

Cl[H].Cl[H].Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)c6[nH]c7[C@@H]8Oc9c(O)ccc%10C[C@H]%11N(CC[C@@]8(c9%10)[C@@]%11(O)Cc7c6C[C@@]35O)CC%12CC%12)CC%13CC%13

InChI

1S/C40H43N3O6.2ClH/c44-25-7-5-21-13-27-39(46)15-23-24-16-40(47)28-14-22-6-8-26(45)34-30(22)38(40,10-12-43(28)18-20-3-4-20)36(49-34)32(24)41-31(23)35-37(39,29(21)33(25)48-35)9-11-42(27)17-19-1-2-19;;/h5-8,19-20,27-28,35-36,41,44-47H,1-4,9-18H2;2*1H/t27-,28-,35+,36+,37+,38+,39-,40-;;/m1../s1

InChI 密鑰

JOJPJLHRMGPDPV-LZQROVCBSA-N

正在寻找类似产品? 访问 产品对比指南

生化／生理作用

高度选择性 κ-阿片受体拮抗剂。

取代透過

产品编号
说明
价格

儲存類別代碼

13 - Non Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

M Dimitrijević et al.
Immunopharmacology, 49(3), 255-262 (2000-09-21)
We have previously demonstrated that central application of leucine-enkephalin (Leu-Enk) elicits potentiation and suppression of humoral immune responses through OP(1) (delta) and OP(2) (kappa) receptors, respectively. Interestingly, both effects were found to be additionally dependent on OP(3) (mu) receptor function.
S A Hjorth et al.
Molecular pharmacology, 47(6), 1089-1094 (1995-06-01)
The structural determinants for the selective binding of the nonpeptide opioid receptor antagonist nor-binaltorphimine (nor-BNI) to the kappa-opioid receptor were characterized using a systematic series of chimeras between the kappa receptor and the homologous mu-opioid receptor. All 10 chimeric constructs
M C Ko et al.
The Journal of pharmacology and experimental therapeutics, 291(3), 1113-1120 (1999-11-24)
Systemic administration of nor-binaltorphimine (nor-BNI) produces a long-lasting kappa-opioid receptor (kappaOR) antagonism and has kappa(1)-selectivity in nonhuman primates. The aim of this study was to establish the pharmacological basis of central kappaOR antagonism in rhesus monkeys (Macaca mulatta). After intracisternal
A E Takemori et al.
The Journal of pharmacology and experimental therapeutics, 246(1), 255-258 (1988-07-01)
Previously, we reported on an opioid antagonist, nor-binaltorphimine (nor-BNI), that had high selectivity for kappa opioid receptors in smooth muscle preparations. In this study, nor-BNI administered either s.c. or i.c.v. was shown to antagonize significantly the antinociceptive effects of the
Juliana Almeida da Silva et al.
European journal of pharmacology, 698(1-3), 235-245 (2013-02-12)
The chemical neuroanatomy and the effects of central administration of opioid antagonists on the innate fear-induced responses elicited by electrical (at escape behaviour threshold) stimulation of the midbrain tectum were determined. The aim of the present work was to investigate
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门